AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00396292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron tablets
Description: 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
Study NCT00396292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-45
Description: A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
Study NCT01780662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00085735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01233973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video
Study NCT02419560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 and Ibrutinib Combination
Description: Both are administered orally once daily.
Study NCT01278368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic resection after preoperative chemotherapy
Description: Pancreatic resection after preoperative chemotherapy
Study NCT00199563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viagra
Description: Sildenafil 100mg daily for 12 weeks
Study NCT00199563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra
Description: Sildenafil 100mg daily for 12 weeks
Study NCT01278368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic resection
Description: Pancreatic resection
Study NCT01204242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
Study NCT02092194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Dose Online HDF
Description: Convection volume; 33-43 L/treatment (140-180 mL/min)
Study NCT02092194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Online HDF
Description: convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
Study NCT03166033 — intervention group
Intervention type: OTHER
Intervention: the disease
Description: Observation the patients and non-patients
Study NCT00881400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
Study NCT00881400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
Study NCT03072056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101
Study NCT01204242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
Study NCT04319224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days
Study NCT04319224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT04319224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT05165784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral vein identification
Description: Femoral vein identification using V technique
Study NCT05165784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral vein identification
Description: Femoral vein identification using palpation technique
Study NCT02834273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stroke education workshops
Study NCT02905708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Activated heating packs
Description: The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
Study NCT02905708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warming Device
Description: forced air-warming inflatable device applied according to standard hospital protocol.
Study NCT02631057 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day
Study NCT02631057 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin tablet (adjustment by each patients)
Study NCT00732914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib (Sutent)
Description: Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
Study NCT00732914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Description: Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
Study NCT04336683 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interstitial and intracavitary brachytherapy
Description: Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
Study NCT04639882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.
Study NCT02475148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Oral capsule, administered twice daily for 7 days in each 21-day cycle
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study NCT02264990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study NCT03473496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART therapy in Relapsed/Refractory multiple myeloma
Description: one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
Study NCT04368156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore® (Vagus nerve stimulation)
Description: Vagus nerve stimulation using the gammacore neurostimulation device
Study NCT01639677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Description: Laparoscopic gastric bypass surgery
Study NCT01639677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic VBG
Description: Laparoscopic vertical banded gastroplasty
Study NCT03445455 — intervention group
Intervention type: DEVICE
Intervention: Tidal volume measurement
Description: Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask.
Study NCT04345744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
Study NCT04345744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
Study NCT04345744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic and 0.2% chlorhexidine mouth rinse
Description: The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
Study NCT04345744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% mouth rinse
Description: The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
Study NCT02057783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity will carry out 3 times per week during 12 weeks for intervention arm
Study NCT01859442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structured responsive interval exercise training programme
Study NCT01859442 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: NO intervention in this group, only standard care (no exercise programme)
Study NCT01195129 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MicroVention Hydrogel coil
Description: Micro Vention Hydrogel Coils
Study NCT01195129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-hydrogel coils
Description: Cerecyte or bare platinum coils
Study NCT01452334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti PD-L1)
Description: Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
Study NCT04381910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610( Irinotecan hydrochloride liposome injection )
Description: LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
Study NCT02972255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: RO7079901 will be administered as per schedule described in individual arm.
Study NCT01501916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: daily dosage of 50 µg Vitamin D3 for 8 weeks
Study NCT01501916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily intake of placebo
Study NCT02475148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02972255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem will be administered as per schedule described in individual arm.
Study NCT02972255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO7049389 Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
Study NCT02972255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem Placebo
Description: Placebo matching to meropenem will be administered as per schedule described in individual arm.
Study NCT01595152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: 8 mg once daily for 60 days
Study NCT01595152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine
Description: 8 mg, once daily for 60 dyas
Study NCT06180954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LOXO-305
Description: Administered orally
Study NCT06180954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Administered orally
Study NCT06180954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LOXO-305
Description: Administered IV
Study NCT03098329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ct/GC screening
Description: Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
Study NCT03824808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
Description: Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
Study NCT03824808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
Study NCT00586495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
Study NCT03469765 — intervention group
Intervention type: OTHER
Intervention: does not apply
Description: biological sample taking: urine, blood
Study NCT03173092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study NCT03173092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules.
Study NCT03173092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone.
Study NCT04019730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: low carbohydrate diet (\< 10 EN% carbs) vs high carbohydrate diet (>50 EN% carbs)
Study NCT00087009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-glucan
Description: Given orally
Study NCT00087009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT03849378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sargassum Horneri Extract group
Description: This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
Study NCT03849378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
Study NCT04361591 — intervention group
Intervention type: OTHER
Intervention: Observational only
Description: Observational Study
Study NCT04149067 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: Evaluation of the effectiveness and safety of the Dapagliflozin treatment.
Study NCT04149067 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Description: Evaluation of the effectiveness and safety of the Sitagliptin treatment.
Study NCT01495221 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alfilbercept
Description: All patients will receive 2.0 mg intravitreal aflibercept injection.
Study NCT03157024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring Sham (RS)
Study NCT01029366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
Study NCT03157024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Needle (RN)
Study NCT03157024 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kim Sham (KS)
Study NCT01384227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
Study NCT01281566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
Study NCT01281566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisapride
Description: 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
Study NCT04422860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum Arabic varnish
Description: Powdered exudate from various Acacia species, especially A. senegal (Leguminosae).
Study NCT04422860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proflourid Varnish,VOCO
Description: 5% NaF varnish
Study NCT04422860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI Varnish,GC Japan Inc.
Description: CPP-ACP with fluoride based varnish
Study NCT00226759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
Study NCT00226759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Study NCT02151474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Study NCT01383993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Study NCT01383993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Study NCT04039074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Yoga
Description: A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice.
Study NCT04162691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue
Description: Four 4-5 mm tissues of the thymoma
Study NCT04039074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Iyengar Yoga
Description: A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
Study NCT04039074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: A 12-week mindfulness intervention designed for the healthy handling of stress.
Study NCT02151474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03302845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 MG
Description: Omeprazole 40 mg capsule
Study NCT03302845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Description: Famotidine 40 mg tablet
Study NCT03302845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg
Description: Telotristat ethyl 250 mg tablet
Study NCT01515384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-133
Description: IV injection, 7.6 mCi (281.2 MBq)